FierceBiotechFierceBiotechResearchFierceBiotechITFierceVaccinesFiercePharmaFiercePharmaManufacturing   FierceHealthcare

Free Newsletter

About | View Sample | Privacy
Related Topics >> AIDS | AIDS vaccine | Merck | Dennis Burton | Eric Hunter

Planned AIDS vaccine trial raises concerns

Tools
  • Email
  • Print
  • Comment
  • Contact Author
  • Reprint

The AIDS Vaccine Research Subcommittee of the NIH has OK'd a new AIDS vaccine trial, prompting some skeptics to caution against plunging back into trials so soon after a Merck program misfired.

"We're redesigning the aims of human HIV vaccine research without redesigning the vaccine," said Scripps Research Institute immunologist Dennis Burton. "Let's not go into a human experiment without a clear idea of what we're going to learn."

Emory University's Eric Hunter, though, said the new vaccine was sufficiently different from Merck's to warrant a study. The vaccine is based on the adenovirus type 5 and given after a schedule of three DNA-based immunizations aimed at priming the human immune system. Merck's vaccine was administered without the DNA priming.

- read the article from The Scientist

ALSO: Researchers at Mymetics insists that a new HIV vaccine can be successful by building on the experiences of the past 20 years. Release

Related Articles:
Feds steering funds back to basic AIDS vax research
AIDS vaccine researchers years away from success
Merck's HIV vaccine linked to higher infections rate
Merck halts study of "ineffective" HIV vaccine

More stories about AIDS   AIDS vaccine   Merck   Dennis Burton   Eric Hunter  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

To combat spam, please enter the code in the image.